Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

NCT00405808 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2666

Enrollment

INDUSTRY

Sponsor class

Stopped EMEA recommendation to suspend Acomplia marketing authorisation

Conditions

Obesity

Interventions

DRUG: Rimonabant
DRUG: Placebo

Sponsor

Sanofi